3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
31
Phase 1/2
26
Phase 1
26
Phase 3
7
Phase NA
1
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Skin Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Melanoma
2
Carcinoma, Hepatocellular
2
Turcot syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasm Metastasis
1
Neoadjuvant Therapy
1
Mouth Neoplasms
1
Malignant Ascites
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Small Cell
1
Carcinoma, Endometrioid
1
Carcinoma
1
Interventions
Nephroureterectomy
2
Lymph Node Excision
2
Cystectomy
2
pembrolizumab
1
enfortumab vedotin
1
Water
1
Urinalysis
1
Ultrasonography
1
Tomography, Optical Coherence
1
Standard of Care
1
Sodium Chloride
1
Single Person
1
Resistance Training
1
Radiosurgery
1
Practice Guidelines as Topic
1
Optical Imaging
1
Narrow Band Imaging
1
Interviews as Topic
1
High-Intensity Focused Ultrasound Ablation
1
Fluorodeoxyglucose F18
1
Extracorporeal Shockwave Therapy
1
Exercise Test
1
Exercise
1
Cryosurgery
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Carcinoma, Transitional Cell
×
pembrolizumab
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled